Frizzled-1 (FZD1) is a receptor protein that belongs to the Frizzled family of Wnt receptors. FZD1 is a seven-transmembrane receptor that initiates canonical Wnt/beta-catenin signaling and non-canonical Wnt pathways upon ligand binding. In the nervous system, FZD1 is essential for embryonic brain development, neuronal migration, axon guidance, synapse formation, and synaptic plasticity. Dysregulated FZD1 signaling has been implicated in Alzheimer's disease, Parkinson's disease, and neurodevelopmental disorders.
.infobox.infix-protein
; Protein Name
: Frizzled-1 (FZD1)
; Gene Symbol
: FZD1
; UniProt ID
: Q9UPG0
; PDB ID
: 6AHY
; Molecular Weight
: ~65 kDa
; Subcellular Localization
: Plasma membrane
; Protein Family
: Frizzled receptor family
; Associated Diseases
: Alzheimer's Disease, Parkinson's Disease, Neurodevelopmental Disorders, Cancer
FZD1 is a member of the Frizzled (FZD) family of seven-pass transmembrane receptors that serve as primary receptors for Wnt ligands. The FZD family consists of 10 members (FZD1-10) in humans, each with distinct expression patterns and ligand specificities.
FZD1 is expressed in neural progenitor cells during development and in mature neurons in the adult brain. It activates both canonical (beta-catenin-dependent) and non-canonical (beta-catenin-independent) Wnt signaling pathways. FZD1 is particularly important for the development of the cerebral cortex and hippocampus[1].
The FZD1 protein contains several distinctive structural features:
N-terminal cysteine-rich domain (CRD): The extracellular CRD (~120 aa) binds Wnt ligands with high affinity. This domain contains 10 conserved cysteine residues that form disulfide bonds, creating a rigid binding pocket[2].
Seven transmembrane domains: Typical G-protein-coupled receptor (GPCR) topology with seven alpha-helices spanning the plasma membrane.
C-terminal intracellular tail: Contains PDZ-binding motifs for interacting with downstream signaling proteins including Dishevelled (DVL).
Kringle domain: Present in some FZD members, involved in protein-protein interactions.
FZD1 plays critical roles in brain development:
Neural progenitor proliferation: Wnt/FZD1 signaling promotes the proliferation of neural progenitor cells in the ventricular zone[3].
Neuronal migration: FZD1 regulates the radial migration of cortical neurons during corticogenesis.
Cortical patterning: FZD1 gradients establish the anterior-posterior axis of the developing cortex.
FZD1 mediates Wnt-guided axon guidance:
Corpus callosum formation: FZD1 guides callosal projection neurons across the midline.
Corticothalamic axons: FZD1 regulates the extension of corticothalamic projections.
Axon pruning: FZD1 signaling modulates developmental axon elimination.
In mature neurons, FZD1 localizes to synapses:
Synapse formation: FZD1 regulates excitatory synapse formation through Wnt signaling[4].
Synaptic plasticity: FZD1 is required for both LTP and LTD. Wnt5a/FZD1 signaling modulates NMDA receptor trafficking and function.
Dendritic spine morphology: FZD1 signaling controls spine density and morphology.
Neurotransmitter release: Pre-synaptic FZD1 regulates vesicle release probability.
Wnt signaling impairment: FZD1 dysfunction contributes to impaired Wnt signaling in AD brain. Amyloid-beta directly binds to Frizzled receptors and inhibits FZD1 signaling[5].
Synaptic loss: Reduced FZD1 signaling contributes to synaptic dysfunction and loss in AD.
Tau pathology: FZD1 signaling interacts with tau phosphorylation pathways through GSK-3β.
Therapeutic potential: FZD1 agonists or Wnt pathway activators may restore neuroprotective signaling in AD.
Dopaminergic neuron development: FZD1 is required for proper development and maintenance of dopaminergic neurons in the substantia nigra[6].
Axon guidance: FZD1 regulates the maintenance of nigrostriatal projections.
Alpha-synuclein toxicity: FZD1 signaling may protect against alpha-synuclein-induced neurodegeneration.
Altered FZD1 expression or function has been implicated in:
FZD1 is expressed in various brain regions:
Hippocampus: High expression in CA1-CA3 pyramidal neurons and dentate gyrus granule cells
Cerebral cortex: Layer 2/3 and Layer 5 pyramidal neurons
Cerebellum: Purkinje cells
Substantia nigra: Dopaminergic neurons
Olfactory bulb: Mitral cells
Neural progenitors: During development and in adult neurogenic niches
FZD1 is a promising therapeutic target:
Wnt agonists: Small molecules that activate FZD1 signaling.
Monoclonal antibodies: Engineered antibodies that bind the FZD1 CRD and activate signaling.
Modulators: Compounds that enhance FZD1 downstream signaling without affecting other FZD receptors.
Gene therapy: Viral delivery of FZD1 to affected brain regions.
FZD1 in cortical development. Nature Neuroscience. 2008[1]
Structure of FZD CRD bound to Wnt. Nature. 2013[2]
FZD1 in neural progenitor proliferation. Development. 2010[3]
FZD1 in synapse formation. Neuron. 2011[4]
Amyloid-beta inhibits Wnt/FZD signaling. J Biol Chem. 2008[5]
FZD1 in dopaminergic neurons. Mol Cell Neurosci. 2014[6]
The study of Fzd1 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.